Theravance, Inc. (Nasdaq: THRX) has appointed Theodore Witek as Senior Vice President, Clinical and Medical Affairs, Respiratory. Prior to joining Theravance, Witek served as President and Chief Executive Officer at Boehringer Ingelheim Canada, Limited. Witek’s previous positions at Boehringer Ingelheim include: Managing Director at Boehringer Ingelheim Portugal; Vice President & Head, SPIRIVA Development & Operations at Boehringer Ingelheim GmbH; Vice President, Clinical & Scientific Affairs, Head, Respiratory & Immunology Group, and Director, Respiratory & Immunology Group at Boehringer Ingelheim Pharmaceuticals. 

Witek received his M.B.A. from Henley Management College, his Doctor of Public Health from Columbia University, his Masters of Public Health from Yale University, and both his B.S. in Health Sciences – Respiratory Care and A.S. in Respiratory Therapy Sciences from Quinnipiac College. 

About Theravance, Inc.  

Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. Theravance's key programs include: RELVAR® ELLIPTA® or BREO® ELLIPTA™ (FF/VI), ANORO™ ELLIPTA™ (UMEC/VI) and MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist), each partnered with GlaxoSmithKline plc, and its oral Peripheral Mu Opioid Receptor Antagonist program. By leveraging its proprietary insight of multivalency to drug discovery, Theravance is pursuing a best-in-class strategy designed to discover superior medicines in areas of significant unmet medical need. For more information, please visit Theravance's web site at